This industry-sponsored symposium, held at ELCC 2025, has been organised and funded by Regeneron.
The views expressed in these videos are those of the speakers and do not necessarily reflect the views of Regeneron. This is a non-promotional Symposium, it contains off-licence data. This content is intended for healthcare professionals only. Drugs may be investigational, not approved, or subject to additional monitoring. Please consult the local prescribing information and report any adverse events according to the regulations in your country.
Welcome and Opening
First Things First: Identifying Novel Targets for Non-oncogene-driven NSCLC
Leveraging the Therapeutic Timeline: Sequencing of ICIs and Chemotherapy to Derive Treatment Benefit After Initial Progression
Time is Ticking: A look at the Prevailing Unmet Needs for Second-line Strategies in Non-oncogene-driven NSCLC
Q&A
At the European Lung Cancer (ELCC) 2025, renowned experts Nicolas Girard, Andrea Ardizzoni and Alfredo Addeo discuss the following:
- Novel targets for non-oncogene driven NSCLC in the first line
- Sequencing immune checkpoint inhibitors and chemotherapy to derive benefit after progression
- Unmet needs for second-line strategies in non-oncogene-driven NSCLC
Speakers
Nicolas Girard1
Andrea Ardizzoni2
Alfred Addeo3
1. Institut Curie, Paris, France
2. University of Bologna, Italy
3. University Hospital of Geneva, Switzerland
